The funding will enable Aclid to meet customer demand for its real-time screening and verification platform. The financing was led by 2048 Ventures and IA Ventures.

Aclid is the security and compliance automation platform for biotechnology. Gene synthesis providers use Aclid to verify customers, screen DNA and RNA orders for pathogenic and toxic elements, and automate compliance checks. As the bioeconomy becomes more accessible and grows from the adoption of digital tools, lab automation, and AI, it also creates new security concerns. Aclid is growing the bioeconomy by making genetic engineering more accessible and safer.